New Cousteau-Linked...
Health Care: Drugs
Array BioPharma Inc. (ARRY: NASDAQ)
$3.38 -0.04 | -1.17%
06/04/12 - 04:00 PM ET
Company Cash Flow
| Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -56.32M | -77.63M | -127.82M | -96.29M |
| Operating Gains/Losses | 4.45M | -1.30M | -11.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | -818.00K |
| (Decrease) Increase In Payables | -585.00K | -1.06M | 1.82M | -1.74M |
| (Decrease) Increase In Other Current Liabilities | 372.00K | 4.72M | -6.98M | 38.03M |
| (Increase) Decrease In Other Working Capital | -30.05M | 75.04M | 839.00K | 0.00 |
| Other Non-Cash Items | 9.70M | 12.11M | 31.77M | 8.03M |
| Net Cash From Continuing Operations | -65.94M | 17.56M | -92.94M | -45.74M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -65.94M | 17.56M | -92.94M | -45.74M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 129.01M | 0.00 | 0.00 | 130.50M |
| Purchases of Property, Plant & Equipment | -1.90M | -1.25M | -2.94M | -8.19M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -53.04M | -78.78M | -19.14M | -71.59M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 74.07M | -69.06M | 29.00M | 50.73M |
| Issuance of Debt | 0.00 | 40.00M | 40.00M | 40.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 7.55M | 12.77M | 1.69M | 1.79M |
| Repayment of Long-Term Debt | -150.00K | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -281.00K | -1.62M | -1.00M | -1.00M |
| Net Cash From Financing Activities | 7.12M | 51.15M | 40.69M | 40.79M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 15.25M | -356.00K | -23.25M | 45.78M |
Portfolios with ARRY
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
- ContributorUnder-$10 Setting Up To Tra...
- UserASCO 2010
- ContributorBarron's Activist Stocks 1-...
- UserPART 6 JPMorgan 28th Annual...
- ContributorBarron's Activist Stocks 1-...
- ContributorBarron's Activist Stocks 1-...
Latest ARRY Headlines from TheStreet
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - 7 Stocks Under $10 Making Big Moves 05.17.12 | 12:05 pm
- Biotech Stock Live Chat Recap: ASCO & Obesity 05.17.12 | 11:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Hot Biotech Stocks Traded by Hedge Funds in First Quarter 05.16.12 | 07:05 am
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- Array BioPharma Stock Gaps Down On Today's Open (ARRY) 02.09.12 | 08:02 am
Press Releases for ARRY
- Promising Data For KRAS Mutant Advanced NSCLC Patients Presented At ASCO - Business Wire 06.04.12 | 05:06 pm
- MEK162 Shows Promising Clinical Activity In Ongoing Phase 2 Trial - Business Wire 06.04.12 | 04:06 pm
- Array BioPharma To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 05.30.12 | 03:05 pm
- Array BioPharma And Genentech's Strategic Alliance Voted Breakthrough Alliance Of 2012 - Business Wire 05.14.12 | 06:05 pm
- Liam Ratcliffe, M.D., Ph.D., Independent Director, Array BioPharma Board Of Directors (Photo: Business Wire) - Business Wire 04.30.12 | 08:04 am
- Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2012 On April 30, 2012 - Business Wire 04.23.12 | 04:04 pm
- Array BioPharma Names Howard Holden, Ph.D., Vice President Of Regulatory Affairs And Quality Assurance - Business Wire 04.16.12 | 08:04 am
- Encouraging Selumetinib Results Announced For Phase 2 Trial In Ovarian Cancer - Business Wire 04.04.12 | 09:04 am
- Array BioPharma To Present At The Cowen And Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 01:02 pm
- Array BioPharma Announces Closing Of Public Offering Of Common Stock And Exercise Of Overallotment Option - Business Wire 02.14.12 | 09:02 am
Partner Headlines for ARRY
- Array BioPharma Says Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer - Benzinga 04.04.12 | 09:04 am
- Company News for February 10, 2012 - Corporate Summary - Zacks 02.10.12 | 10:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- Array BioPharma Names Gwen A. Fyfe, M.D. to Board of Directors - Benzinga 01.30.12 | 04:01 pm
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.03.11 | 09:11 am
- Bottom Bounce for Array BioPharma - Seeking Alpha 06.29.11 | 09:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- How Array Got Its Groove Back - SeekingAlpha.com 04.28.10 | 01:04 pm
- Biotech Gets Busy With Small Company Financings - SeekingAlpha.com 04.25.10 | 08:04 am
- Array and Novartis Ink Deal - Analyst Blog - Zacks 04.22.10 | 02:04 pm
